News Daily News Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse Todd Neale January 21, 2022
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC Heart Failure 2021 Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR Shelley Wood July 06, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA Michael O'Riordan April 26, 2021
News Daily News Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF Michael O'Riordan April 15, 2021
News Conference News AHA 2020 Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF Todd Neale November 16, 2020
News Conference News AHA 2020 Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF Todd Neale November 13, 2020
News Daily News Higher Risk of HF After ACS for Women Previously on Beta-blockers Michael O'Riordan July 16, 2020
News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Industry News U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure June 26, 2019
News Daily News Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis Caitlin E. Cox January 08, 2018
Presentation AHA 2016 Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF) Presenter: Dirk J. van Veldhuisen November 16, 2016